[go: up one dir, main page]

WO2016042567A1 - Formulation de metformine à libération prolongée - Google Patents

Formulation de metformine à libération prolongée Download PDF

Info

Publication number
WO2016042567A1
WO2016042567A1 PCT/IN2014/000602 IN2014000602W WO2016042567A1 WO 2016042567 A1 WO2016042567 A1 WO 2016042567A1 IN 2014000602 W IN2014000602 W IN 2014000602W WO 2016042567 A1 WO2016042567 A1 WO 2016042567A1
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
instamodel
pharmaceutical composition
solid pharmaceutical
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2014/000602
Other languages
English (en)
Inventor
Suresh Pareek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/IN2014/000602 priority Critical patent/WO2016042567A1/fr
Publication of WO2016042567A1 publication Critical patent/WO2016042567A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)

Definitions

  • WO 201 1060256, WO 2003039527 and WO 2005123134 disclose the use of hydrophilic polymers like hypromellose for extended release of drug like metformin. These polymers extend the release of drug by showing osmosis nature in aqueous conditions.
  • Cellulosic matrix based system work by the swelling and gelling function i.e. these polymer swell through influx of liquids and a gel like physical structure is formed which provides extended release effect facilitated by diffusion of the Metformin.
  • Some patents that disclose matrix based systems for slow release of metformin include WO 20071 361 5 1 and US 5955 1 06.
  • Metformin is blended with the ready to use polymer and aqueous granulated further the granulated mixture is compressed to produce a solid formulation.
  • the ingredients are blended to form a uniform powder and then compressed with means generally known to skilled in the art.
  • Metformin and INSTAMODEL are blended together with binding agent and thereafter wet granulated and dried. These dried granules are then processed in presence o f lubricant and gl idant, and thereafter compressed to form appropriate dosage form and optionally coated .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique sèche prête à l'emploi à libération modifiée destinée à des formes pharmaceutiques de metformine et de ses sels et dérivés, un procédé de préparation de comprimé à libération prolongée faisant appel à l'INSTAMODEL (A43D00041 et A43D00042) fabriqué par Ideal Cures Private Limited à Mumbai en Inde, ainsi que son utilisation comme additif dans des aliments pour animaux, des aliments et des compléments alimentaires et également des compositions cosmétiques et pharmaceutiques. L'invention concerne également des compositions à libération modifiée prêtes à l'emploi permettant de réguler la libération de metformine à des dosages différents, un procédé de production de celles-ci ainsi que leur utilisation comme compositions pharmaceutiques formulées.
PCT/IN2014/000602 2014-09-16 2014-09-16 Formulation de metformine à libération prolongée Ceased WO2016042567A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000602 WO2016042567A1 (fr) 2014-09-16 2014-09-16 Formulation de metformine à libération prolongée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000602 WO2016042567A1 (fr) 2014-09-16 2014-09-16 Formulation de metformine à libération prolongée

Publications (1)

Publication Number Publication Date
WO2016042567A1 true WO2016042567A1 (fr) 2016-03-24

Family

ID=55532652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000602 Ceased WO2016042567A1 (fr) 2014-09-16 2014-09-16 Formulation de metformine à libération prolongée

Country Status (1)

Country Link
WO (1) WO2016042567A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039527A1 (fr) * 2001-11-06 2003-05-15 Ranbaxy Laboratories Limited Comprimes de metmorphine a liberation controlee
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20040109891A1 (en) * 2002-08-02 2004-06-10 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004110422A1 (fr) * 2003-06-16 2004-12-23 Ranbaxy Laboratories Limited Comprimes a liberation controlee de metformine
WO2006082523A2 (fr) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Compositions pharmaceutiques de metformine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039527A1 (fr) * 2001-11-06 2003-05-15 Ranbaxy Laboratories Limited Comprimes de metmorphine a liberation controlee
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20040109891A1 (en) * 2002-08-02 2004-06-10 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004110422A1 (fr) * 2003-06-16 2004-12-23 Ranbaxy Laboratories Limited Comprimes a liberation controlee de metformine
WO2006082523A2 (fr) * 2005-01-25 2006-08-10 Aurobindo Pharma Limited Compositions pharmaceutiques de metformine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IDEAL CURE PVT.LTD: "Extended Release Tablets Formulation Simplified", 19 July 2012 (2012-07-19), Retrieved from the Internet <URL:http://news.cision.com/ideal-cures-pvt--ltd/r/extended-release-tablets-formulation-simplified,c9285826> *

Similar Documents

Publication Publication Date Title
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
EA016850B1 (ru) Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
CA2766884C (fr) Compositions a dose pharmaceutique solide fixe comprenant de l&#39;irbesartan et de l&#39;amlodipine, leur preparation et leur application therapeutique
EP2726064B1 (fr) Forme orale pharmaceutique à libération contrôlée contenant oxycodone
JP6461142B2 (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
EP2010158B1 (fr) Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
RU2613192C1 (ru) Таблетки клозапина с пролонгированным высвобождением
WO2006123213A1 (fr) Preparations a liberation modifiee de gliclazide
WO2016042567A1 (fr) Formulation de metformine à libération prolongée
CN110913843B (zh) 药物组合物
WO2016042568A1 (fr) Formulation à libération prolongée de gliclazide
WO2016042569A1 (fr) Préparation à libération prolongée de diclofénac
RU2603469C2 (ru) Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления
WO2016042570A1 (fr) Formulation à libération prolongée d&#39;acétaminophène
CA3048968A1 (fr) Composition pharmaceutique orale de lurasidone et sa preparation
WO2016042566A1 (fr) Formulation de trimétazidine à libération prolongée
WO2016042564A1 (fr) Formulation à libération prolongée d&#39;acéclofénac
WO2016042563A1 (fr) Formulation à libération prolongée de carbamazépine
WO2016042565A1 (fr) Formulation à libération prolongée de métoprolol
EP4520322A1 (fr) Compositions pharmaceutiques contenant de l&#39;enzalutamide
EP4456983A1 (fr) Compositions pharmaceutiques comprenant du macitentan comme principe actif et d&#39;autres excipients pertinents
HU231592B1 (hu) Favipiravir tartalmú gyógyszerkészítmény, ennek előállítása és alkalmazása

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14902254

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14902254

Country of ref document: EP

Kind code of ref document: A1